Immuron Limited (IMRN)
IMRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1660046/000121390026102838/0001213900-26-102838-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-06-30. Converted from AUD at 1.4738 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | IMRN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | 2017 |
| SEC CIK | 0001660046 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Australia |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $5.2M |
| Net income | -$2.5M |
| Operating income | -$2.6M |
| Net margin | -47.7% |
| Operating margin | -49.9% |
| Revenue growth | +2.5% |
| Cash | $6.1M |
| Total assets | $8.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Reported in AUD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-09-24 |
| Cash and burn | $6.1M cash; operating cash flow -$553K a quarter. | Report 2026-06-30 |
| Shares outstanding | 8,071,202 (2026-06-30); 5,848,975 a year earlier. | Cover page 2026-06-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-10-23 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton Audit Pty Ltd, Melbourne, Australia | PCAOB Form AP 2026-10-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | $5.2M | -$2.5M | -$2.2M | $6.1M | No debt tags | $5.2M | 20-F 2026-09-24 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-10-23 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-09-24 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 428 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.3% |
| 1 month | -15.9% |
| 3 months | -22.6% |
| Year to date | +14.7% |
| 1 year | -43.9% |
| From 52-week high | -52.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CURX | Curanex Pharmaceuticals Inc | $4.63 | -0.11% | $7.3M |
| GTBP | GT Biopharma Inc. | $3.54 | -1.81% | $7.3M |
| LGVN | Longeveron Inc. | $2.14 | -14.06% | $7.2M |
| UPC | Universe Pharmaceuticals Inc. | $1.48 | -1.99% | $7.4M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| MBRX | Moleculin Biotech Inc. | $7.14 | -9.28% | $7.6M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier